Articles

Find an Article

Filter articles

Applied Filters

Showing 11 to 20 of 122 results

I-MAK: saving lives by curing the patent system

International, US19-10-2018

Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.

SPC waiver: good intentions, but not the right deal?

EU17-10-2018

The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.

USITC: a powerful forum for biologics patent owners

US10-10-2018Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang

Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.

A patent attack on three fronts

India02-10-2018Neeti Wilson, Arpita Kulshreshtha and Gitika Suri

A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.

Two new weapons for defending Hatch-Waxman litigation

US03-09-2018Mark Remus

Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.

SPC export waiver: a long road ahead

EU23-08-2018Trevor Cook

The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.

LSIPR 50 2018: Brian Anderson

US22-08-2018

Brian Anderson was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

Combination SPCs: shaken and stirred

UK14-08-2018Joel Beevers and Michael Pears

Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate.

Hatch-Waxman amendment: a Hobson’s choice

US08-08-2018Janine Carlan

If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.

LSIPR 50 2018: Patrick Leahy

US23-07-2018

Patrick Leahy was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the government and policy section, as LSIPR reports.

Showing 11 to 20 of 122 results

LSIPR